Hemogenyx Pharmaceuticals Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOPHF research report →
About the company
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome.
- CEO
- Vladislav Sandler
- IPO
- 2021
- Employees
- 16
- HQ
- London, GB
Price Chart
- Market Cap
- $15.84M
- P/E
- -3.48
- P/S
- 0.00
- P/B
- 38.91
- EV/EBITDA
- -8.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2807.75%
- ROIC
- -148.02%
- Revenue
- $0 · 0.00%
- Net Income
- $-9,760,364 · -73.70%
- EPS
- $-2.20 · -3.29%
- Op Income
- $-6,980,258
- FCF YoY
- 16.89%
- 52W High
- $2.33
- 52W Low
- $0.04
- 50D MA
- $2.33
- 200D MA
- $2.33
- Beta
- 1.53
- Avg Volume
- 16.31K
Get TickerSpark's AI analysis on HOPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HOPHF coverage
Recent articles, reports, and earnings notes.
No research on HOPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HOPHF report →Similar companies
Peers in the same neighborhood.